We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Brian D. Nicholson
Brian D. Nicholson
Products
PRODUCTS
Akorn, Inc.
Brian D. Nicholson
Price:
$117.00
View
Hydrox Laboratories, Inc.
Brian D. Nicholson
Price:
$117.00
View
Bajaj Medical, LLC
Brian D. Nicholson
Price:
$117.00
View
Morton Grove Pharmaceuticals, Inc.
Brian D. Nicholson
Price:
$117.00
View
KIK Custom Products
Brian D. Nicholson
Price:
$117.00
View
Nanophase Technologies Corp.
Brian D. Nicholson
Price:
$117.00
View
Baxter Healthcare Corp.
Sean T. Creighton
,
Andrew A. Leboeuf
,
Brian D. Nicholson
, and
James W. Plucinski
Price:
$117.00
View
Praxair Distribution, Inc.
Brian D. Nicholson
Price:
$117.00
View
AVA Inc.
Brian D. Nicholson
and
Chad J. Whitwell
Price:
$117.00
View
Axium Healthcare Pharmacy dba Balanced Solutions Compounding
Thomas E. Friel
,
Brian D. Nicholson
, and
German Rivera
Price:
$117.00
View
View All Products by Brian D. Nicholson
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More